An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI.
deep learning
diagnosis
dynamic susceptibility contrast
glioblastoma
lymphoma
metastasis
neuro-oncology
perfusion MRI
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
30
08
2023
revised:
16
11
2023
accepted:
15
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
Noninvasive differential diagnosis of brain tumors is currently based on the assessment of magnetic resonance imaging (MRI) coupled with dynamic susceptibility contrast (DSC). However, a definitive diagnosis often requires neurosurgical interventions that compromise patients' quality of life. We apply deep learning on DSC images from histology-confirmed patients with glioblastoma, metastasis, or lymphoma. The convolutional neural network trained on ∼50,000 voxels from 40 patients provides intratumor probability maps that yield clinical-grade diagnosis. Performance is tested in 400 additional cases and an external validation cohort of 128 patients. The tool reaches a three-way accuracy of 0.78, superior to the conventional MRI metrics cerebral blood volume (0.55) and percentage of signal recovery (0.59), showing high value as a support diagnostic tool. Our open-access software, Diagnosis In Susceptibility Contrast Enhancing Regions for Neuro-oncology (DISCERN), demonstrates its potential in aiding medical decisions for brain tumor diagnosis using standard-of-care MRI.
Identifiants
pubmed: 38471504
pii: S2666-3791(24)00108-3
doi: 10.1016/j.xcrm.2024.101464
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101464Informations de copyright
Copyright © 2024. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.